1.	Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Phase: Phase IV Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: KMUH-IRB-960043, NCT00834860
2.	Pegylated Interferon-alpha-2a in Patients With Malignant Melanoma Stage IIA-IIIB Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: ML17840, NCT00204529
3.	Phase I/II Pilot Study of Gefitinib and PEG-Interferon alfa-2a in Patients With Unresectable or Metastatic Squamous Cell Carcinoma of the Skin. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCSD-051205, ZENECA-IRUSIRES0488, NCT00423397
4.	AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year Phase: Phase II Type: Treatment Status: Closed Age: 18 to 90 Sponsor: Other Protocol IDs: 2003.317, NCT00146913
5.	Pegasys® in Patients With Myeloproliferative Diseases Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: DM03-0109, NCT00452023
6.	Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Phase: Phase II Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: PVN1, NCT00241241
7.	PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma Phase: Phase I Type: Treatment Status: Completed Age: 18 months to 21 years Sponsor: NCI, NIH WGMCC Protocol IDs: 050232, 05-C-0232, NCI-P6670, CDR0000448811, NCI-05-C-0232, NCT00253474